Brian Burlew, MD
Pulmonary Disease · Bethlehem, PANPI 1598712119
Payments from drug & device makers
Across 353 payments — averaging $221.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$59K
- AstraZeneca$15K
- GSK$2K
- United Therapeutics Corporation$432
- Actelion Pharmaceuticals US, Inc.$267
- Harmony Biosciences LLC$172
- plus $1K from 22 others
What the payments were for
- Consulting fees$6,0088%
- Speaking & faculty fees$60,34877%
- Travel & lodging$2,9984%
- Food & beverage$8,78811%
- Education$1290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 113 | $59,296 |
| AstraZeneca(2 entities) | 83 | $15,318 |
| GSK | 79 | $1,652 |
| United Therapeutics Corporation | 9 | $432 |
| Actelion Pharmaceuticals US, Inc. | 12 | $267 |
| Harmony Biosciences LLC | 7 | $172 |
| E.r. Squibb & Sons, L.L.C. | 3 | $132 |
| Regeneron Healthcare Solutions, Inc. | 4 | $99 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $92 |
| Grifols USA, LLC | 4 | $83 |
| Philips North America LLC | 4 | $65 |
| Paratek Pharmaceuticals, Inc. | 2 | $64 |
| Jazz Pharmaceuticals Inc. | 3 | $64 |
| Genentech USA, Inc. | 3 | $64 |
| Advanced Respiratory, Inc | 3 | $63 |
| Sanofi | 3 | $58 |
| Baxter Healthcare | 3 | $55 |
| Ambu Inc. | 2 | $54 |
| Mylan Specialty L.p. | 2 | $30 |
| Sunovion Pharmaceuticals Inc. | 2 | $30 |
| Pharming Healthcare, Inc. | 1 | $28 |
| Amgen | 1 | $27 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Shire North American Group Inc | 1 | $23 |
| Merck | 1 | $22 |
| Circassia Inc. | 1 | $20 |
| Vapotherm Inc | 1 | $19 |
| Phadia US Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$78,270 in reported general payments places this provider in the 85th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 73 | $1,066,153 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 631 | $534,779 |
| Breo ElliptaFluticasone/Vilanterol | 468 | $238,491 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 393 | $226,225 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $114,590 |
| Dupixent PenDupilumab | 22 | $79,052 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 94 | $68,958 |
| Arnuity ElliptaFluticasone Furoate | 189 | $63,712 |
| EliquisApixaban | 62 | $60,774 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 296 | $57,081 |
| Spiriva RespimatTiotropium Bromide | 73 | $55,634 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 88 | $55,196 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 66 | $45,572 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 960 | $36,885 |
| SymbicortBudesonide/Formoterol Fumarate | 75 | $30,008 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $59,296 | $1,222,555300 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $1,652 | $1,077,9541,704 claims |
| Grifols USA, LLCProlastin C | $83 | $114,59012 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $15,318 | $106,717192 claims |
| MerckDulera, Asmanex | $22 | $14,84750 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Bethlehem
- Surya BhattBethlehem$880K
- Gerard CrinerPhiladelphia$18.2M
- Sandeep Bansaldu Bois$8.9M
- David WheelerPhiladelphia$7.7M
- Steven AlbeldaPhiladelphia$5.5M
- Paul SimonelliDanville$2.1M
- Kevin GibsonPittsburgh$1.3M
- Frank SciurbaPittsburgh$1.2M
- Joseph PilewskiPittsburgh$1M
- Steven DuncanPittsburgh$995K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.